Company profile
Digicann Ventures Inc.
OTC: AGFAF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, BCReports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
16DFH 8DQ —GM 31SS 37
v0.1 · 45/100 weight · provisional
↑ growth stability, disclosure history · ↓ 3-yr revenue growth, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$306.6k
Employees
—
as of 2026-08-28
Market cap
$86.6k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2025
Net income-$306.6k-428.5k CAD2025
Operating income-$382.4k-534.5k CAD2025
Total assets$136.9k187.7k CAD2025
Liabilities$1.2M1.7M CAD2025
Equity-$1.0M-1.4M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Digicann Ventures Inc.’s revenue?
Digicann Ventures Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Drug Free Solution, Inc.——Nascent Biotech, Inc.——ProtoKinetix, Incorporated——Wellstar International, Inc.——Wesana Health Holdings Inc.——Pathfinder Cell Therapy, Inc.——Key facts
CEONicholas J. Kuzyk
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, BC
ExchangeOTC: AGFAF
Employees—
IPO date2015-07-14
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.